Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

By S. Wilhelm, J. Dumas, Lila Adnane, M. Lynch, Christopher A. Carter, G. Schütz, K. Thierauch, D. Zopf. International Journal of Cancer, 2011

1,301 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018, background): “Second-line therapies Regorafenib Regorafenib is an oral multi-kinase inhibitor that blocks the activity of protein kinases involved in angiogenesis, oncogenesis, and the tumour microenvironment.(596) Regorafenib (160 mg po once daily 3 weeks on / 1 week off) showed survival benefits compared to pla”
Ten years of anti-vascular endothelial growth factor therapy (2016, background): “The broad-spectrum RTKI and RAF kinase inhibitor regorafenib (Stivarga; Onyx, Bayer) 124 is the only kinase inhibitor to be approved by the FDA as a monotherapy for previously treated metastatic colorectal cancer (February 2013) following improved OS in the CORRECT placebo-controlled Phase III…”
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. (2017, background): “15,17 .”
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update (2017, background): “Regorafenib, a novel multikinase inhibitor, has more potent inhibitory activities against multiple angiogenic pathways (VEGFR, PDGFR, TIE2, and FGFR) and oncogenic pathways (RET, KIT, c-RAF/RAF-1, and BRAF) than sorafenib [585].”